Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising.

Interview produced by Prostatepedia

Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer

Summary:

Raoul S. Concepcion, MD, FACS, discusses managing prostate cancer with a combination of immunotherapeutic agents and other treatment options. Sipuleucel-T (PROVENGE), the only FDA approved immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), does not attack androgen receptors. Therefore, Dr. Concepcion explores the possibility combining sipuleucel-T with androgen excess inhibitors, like abiraterone or enzalutamide, or a sipuleucel-T/radium-223 combination.

Dr. Concepcion further discusses combination treatments and the topic of using immunotherapy for prostate cancer in his lecture What’s New in Immunotherapy?

View more Presentations on Immunotherapy

ABOUT THE AUTHOR

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society.

About The Author

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society. Dr. Concepcion completed his residency in general surgery and urology at Vanderbilt University in Nashville, Tennessee, where he was Chief Urology Resident, and later served as a Clinical Associate Professor of Urology. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed the City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. Dr. Concepcion has been in practice since 1990 and has been the principal or co-principal investigator on many clinical trials since then. His clinical interests focus on advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. Dr. Concepcion co-founded CUSP, a urologic research consortium in the United States that specializes in site and patient accrual for the pharmaceutical and biolab industries. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.

Share This

Chat with usLiveChat